Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Endoscopic ablation treatments of dysplastic Barrett's

Argon plasma coagulation and photodynamic therapy are equally effective in eradicating Barrett's mucosa, however, photodynamic therapy is more effective in eradicating dysplasia, reports the latest issue of the Scandanavian Journal of Gastroenterology.

News image

fiogf49gjkf04

Endoscopic mucosal ablation is a promising technique that is used to treat dysplastic Barrett's esophagus.

Dr Krish Ragunath and colleagues from England investigated efficacy and cost-effectiveness of ablation techniques of dysplastic Barrett's esophagus.

The research team compared 2 of these techniques; argon plasma coagulation and photodynamic therapy.

The team included 26 patients with dysplastic Barrett's esophagus, of which 21 were male with a median age of 60 years.

Of these patients, 23 had low-grade dysplasia, and 3 had high-grade dysplasia.

The researchers randomized 13 patients to argon plasma coagulation and 13 to photodynamic therapy.

Barrett's eradicated at 4-month follow-up with photodynamic therapy was 57%
Scandanavian Journal of Gastroenterology

The team performed argon plasma coagulation at a power setting of 65 W and argon gas flow at 1.8 /min in 1 to 6 sessions.

Photodynamic therapy was performed 48 hours after intravenous injection of photofrin 2 mg/kg with a 630 nm red laser light, 200 J/cm through a balloon in 1 session.

All patients received treatment with high-dose proton pump inhibitors.

The researchers undertook cost analysis and the results were assessed by endoscopy and biopsies at 4 months and 12 months after therapy.

The team observed a reduction in the length of Barrett's esophagus in all patients in both groups.

The researchers found that the median length of Barrett's esophagus eradicated at the 4-month follow-up was 65% with argon plasma coagulation.

The median length of Barrett's esophagus eradicated at the 4-month follow-up with photodynamic therapy was 57%.

At the 12-month follow-up, the team found that the median length of Barrett's esophagus eradicated by argon plasma coagulation was 56%.

The researchers also found that the median length of Barrett's esophagus eradicated by photodynamic therapy was 60%.

Dysplasia eradication at 4 months with argon plasma coagulation was 62% and 77% with photodynamic theray.

At 12 months, the team noted that dysplasia eradication with argon plasma coagulation was 67% vs 77% with photodynamic therapy.

Buried columnar glands with intestinal metaplasia were seen in both groups.

The team observed that 1 patient in the photodynamic therapy arm developed adenocarcioma under the neo-squamous epithelium.

Severe adverse events included chest pain and fever in 15%, and 8% with odynophagia using argon plasma coagulation.

The researchers noted that photosensitivity occurred in 15% with photodynamic therapy and 15% with stricture in photodynamic therapy.

The team reported that photodynamic therapy would cost an additional £266 for every percentage reduction in Barrett's length.

In addition, the researchers found that photodynamic therapy costs a further £146 per percentage reduction in dysplasia compared with argon plasma coagulation.

Dr Ragunath's team concludes, “Argon plasma coagulation and photodynamic therapy are equally effective in eradicating Barrett's mucosa.”

"Photodynamic therapy is the more expensive treatment.”

“However, photodynamic therapy is more effective in eradicating dysplasia and the extra benefits are generated at an extra cost.”

“The occurrence of buried columnar glands and carcinoma warrants caution.”

“Long-term follow-up is needed to assess cancer prevention and the durability of the neo-squamous epithelium to justify these interventions.”

Scand J Gastroenterol 2005: 40(7): 750-8
22 August 2005

Go to top of page Email this page Email this page to a colleague

 24 May 2018 
Precision medicine for tumors
 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 23 May 2018 
High body mass index is and ulcerative colitis
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
Fecal incontinence and quality of life in IBD
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Depressive symptoms in IBD youth
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
New therapies for CDI
 15 May 2018 
Hep B in the Grey Zone
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Post‐operative complications in elderly IBD
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Esophageal dilatation in clinical practice 
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's
 24 April 2018 
Microbiome in athletes vs sedentary subjects
 23 April 2018 
Genome-wide study on HBV-related acute-on-chronic liver failure

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us